migraine

Question 1

cafergot moa

Answer 1

Acts on vascular smooth muscles in external carotid network →
Stimulates alpha-adrenergic and 5-HT receptors (esp 1B/D)
→
Vasoconstriction

Question 2

cafergot bioavailability

Answer 2

low

Question 3

cafergot metab

Answer 3

cyp3a inhibitor

Question 4

cafergot avoid with

Answer 4

other cyp3a inhibitors (eg macrolides)

VC agents (ergot alkaloids, sumatriptan, 5HT1 agonists)

Question 5

cafergot se

Answer 5

NV
(hypersensitivity, MI, vascular ischemia)

Question 6

sumatriptan moa

Answer 6

Selective vascular 5HT1d receptor agonist

Constricts carotid arterial circulation but does not alter cerebral blood flow.

Inhibits trigeminal nerve activity

Question 7

sumatriptan protein binding

Answer 7

low

Question 8

sumatriptan elimination

Answer 8

oxidative metabolism (MAO)

Question 9

sumatriptan ci

Answer 9

concurrent maoi, MI

Question 10

sumatriptan se

Answer 10

Dysgeusia, transient BP increase, flushing, pressure, tightness

Question 11

Erenumab moa

Answer 11

Monoclonal antibody CGRP inhibitor.

CGRP: Nociceptive neuropeptide at trigeminal ganglion. Increases with migraine

Question 12

erenumab indication

Answer 12

migraine prophylaxis (≥4d/mth)

Question 13

erenumab kinetics

Answer 13

linear

Question 14

sumatriptan indication

Answer 14

acute tx

Question 15

cafergot indication

Answer 15

acute tx